story of the week
Repotrectinib for ROS1 Fusion–Positive NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
N. Engl. J. Med 2024 Jan 11;390(2)118-131, A Drilon, DR Camidge, JJ Lin, SW Kim, BJ Solomon, R Dziadziuszko, B Besse, K Goto, AJ de Langen, J Wolf, KH Lee, S Popat, C Springfeld, M Nagasaka, E Felip, N Yang, V Velcheti, S Lu, S Kao, C Dooms, MG Krebs, W Yao, MS Beg, X Hu, D Moro-Sibilot, P Cheema, S Stopatschinskaja, M Mehta, D Trone, A Graber, G Sims, Y Yuan, BC ChoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.